3-(2-(6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)pyridin-3-yl)cyclopropyl)benzoic acid | 1268245-17-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-(6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)pyridin-3-yl)cyclopropyl)benzoic acid
• 英文别名: 3-[2-[6-[[5-Cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-(trifluoromethyl)pyridin-3-yl]cyclopropyl]benzoic acid
• CAS: 1268245-17-5
• 化学式: C₂₉H₂₁Cl₂F₃N₂O₄
• 分子量: 589.398
• InChiKey: BCAYBPZWQZVTAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  40
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  85.4
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  [6-[[5-Cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-(trifluoromethyl)pyridin-3-yl]methanol 在 palladium diacetate manganese(IV) oxide 、 lithium hydroxide monohydrate 、 水 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醚 、 氯仿 、 mineral oil 为溶剂， 反应 24.5h， 生成 3-(2-(6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)pyridin-3-yl)cyclopropyl)benzoic acid
  参考文献：
  名称：

  [EN] NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS
  [FR] NOUVEAUX COMPOSÉS SE LIANT AU FXR (NR1 H4) ET MODULANT SON ACTIVITÉ

  摘要：

  本发明涉及结合NR1 H4受体（FXR）并作为NR1 H4受体（FXR）激动剂的化合物。该发明还涉及利用这些化合物制备药物用于通过这些化合物结合所述核受体治疗疾病和/或症状，并涉及这些化合物的合成过程。

  公开号：

  WO2011020615A1

文献信息

• FXR agonists and methods for making and using
  申请人：Salk Institute for Biological Studies

  公开号：US10077268B2

  公开（公告）日：2018-09-18

  Novel FXR agonists are disclosed, embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

  本文公开了新型 FXR 激动剂、其制造方法的实施方案以及包含它们的组合物。还公开了一种治疗或预防受试者代谢紊乱的方法的实施方案，包括向受试者施用（例如通过胃肠道）治疗有效量的一种或多种已公开化合物，从而激活肠道中的 FXR 受体，治疗或预防受试者的代谢紊乱。此外，还公开了一种治疗或预防受试者肠道区域炎症的方法的实施方案，该方法包括向受试者施用（例如，经由胃肠道）治疗有效量的一种或多种所公开化合物，从而激活肠道中的FXR受体，进而治疗或预防受试者肠道区域的炎症。
• FXR AGONISTS AND METHODS FOR MAKING AND USING
  申请人：Salk Institute for Biological Studies

  公开号：EP3116878A1

  公开（公告）日：2017-01-18
• TREATING LATENT AUTOIMMUNE DIABETES OF ADULTS WITH FARNESOID X RECEPTOR AGONISTS TO ACTIVATE INTESTINAL RECEPTORS
  申请人：Salk Institute for Biological Studies

  公开号：EP3267991A1

  公开（公告）日：2018-01-17
• NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS
  申请人：Kremoser Claus

  公开号：US20120232116A1

  公开（公告）日：2012-09-13

  The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.
• INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS
  申请人：Salk Institute for Biological Studies

  公开号：US20180000768A1

  公开（公告）日：2018-01-04

  Disclosed are embodiments of a method of treating or preventing latent autoimmune diabetes of adults (LADA) in a subject. Such embodiments include administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or farnesoid X receptor (FXR) agonist compounds, thereby activating FXR receptors in the intestines, and treating or preventing latent autoimmune diabetes of adults (LADA) in the subject.